Which has stronger earnings & valuation, ANTX or VERU?

Veru has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Veru $16.89M 2.26 -$22.73M -$0.69 N/A

Is ANTX or VERU more profitable?

Veru's return on equity of -47.58% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Veru N/A -47.58% -35.83%

Do analysts recommend VERU or MENS?

Veru currently has a consensus target price of $24.50, indicating a potential upside of 993.75%. Given Veru's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veru is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, VERU or MENS?

Jyong Biotech has lower revenue, but higher earnings than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.26 -$22.73M -$0.69 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is VERU or MENS more profitable?

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Jyong Biotech N/A N/A N/A

Do analysts prefer VERU or SBTX?

Veru presently has a consensus target price of $24.50, indicating a potential upside of 993.75%. Given Veru's stronger consensus rating and higher probable upside, research analysts clearly believe Veru is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VERU or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Silverback Therapeutics N/A -29.62% -28.20%

Is NERV or VERU more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Veru N/A -47.58% -35.83%

Is VERU or CRDL more profitable?

Veru's return on equity of -47.58% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Cardiol Therapeutics N/A -180.44% -140.28%

Veru (VERU) Competitors

$2.24 -0.05 (-2.18%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$2.33 +0.09 (+4.06%)

As of 10/23/2026 07:44 PM Eastern

Compare

VERU vs. ANTX, MENS, SBTX, NERV, and CRDL

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Anthem (ANTX), Jyong Biotech (MENS), Silverback Therapeutics (SBTX), Minerva Neurosciences (NERV), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Anthem?

Anthem (NASDAQ:ANTX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

90.5% of Anthem shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Veru's return on equity of -47.58% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Veru	N/A	-47.58%	-35.83%

Veru has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Veru	$16.89M	2.26	-$22.73M	-$0.69	N/A

Anthem has a beta of -0.98, indicating that its stock price is 198% less volatile than the broader market. Comparatively, Veru has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market.

In the previous week, Anthem had 2 more articles in the media than Veru. MarketBeat recorded 2 mentions for Anthem and 0 mentions for Veru. Anthem's average media sentiment score of 0.00 equaled Veru'saverage media sentiment score.

Company	Overall Sentiment
Anthem	Neutral
Veru	Neutral

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 153.52%. Veru has a consensus price target of $24.50, suggesting a potential upside of 993.75%. Given Veru's stronger consensus rating and higher probable upside, analysts clearly believe Veru is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Veru beats Anthem on 9 of the 13 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Veru (NASDAQ:VERU) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

47.2% of Veru shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Jyong Biotech had 1 more articles in the media than Veru. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Veru. Veru's average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
Veru	Neutral
Jyong Biotech	Neutral

Veru has a beta of -1.21, indicating that its stock price is 221% less volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Jyong Biotech	N/A	N/A	N/A

Jyong Biotech has lower revenue, but higher earnings than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.26	-$22.73M	-$0.69	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Veru currently has a consensus target price of $24.50, indicating a potential upside of 993.75%. Given Veru's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veru is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Veru beats Jyong Biotech on 6 of the 11 factors compared between the two stocks.

How does Veru compare to Silverback Therapeutics?

Veru (NASDAQ:VERU) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Veru has a beta of -1.21, indicating that its share price is 221% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Veru presently has a consensus target price of $24.50, indicating a potential upside of 993.75%. Given Veru's stronger consensus rating and higher probable upside, research analysts clearly believe Veru is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Veru has higher revenue and earnings than Silverback Therapeutics. Veru is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.26	-$22.73M	-$0.69	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

In the previous week, Veru's average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company	Overall Sentiment
Veru	Neutral
Silverback Therapeutics	Neutral

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Silverback Therapeutics	N/A	-29.62%	-28.20%

47.2% of Veru shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Veru and Silverback Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Veru compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

Minerva Neurosciences' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Veru	N/A	-47.58%	-35.83%

Minerva Neurosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market. Comparatively, Veru has a beta of -1.21, indicating that its share price is 221% less volatile than the broader market.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Veru has higher revenue and earnings than Minerva Neurosciences. Veru is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Veru	$16.89M	2.26	-$22.73M	-$0.69	N/A

In the previous week, Minerva Neurosciences' average media sentiment score of 0.00 equaled Veru'saverage media sentiment score.

Company	Overall Sentiment
Minerva Neurosciences	Neutral
Veru	Neutral

Minerva Neurosciences presently has a consensus price target of $10.33, indicating a potential upside of 349.28%. Veru has a consensus price target of $24.50, indicating a potential upside of 993.75%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Veru beats Minerva Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Veru compare to Cardiol Therapeutics?

Veru (NASDAQ:VERU) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Veru's return on equity of -47.58% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Veru has a beta of -1.21, meaning that its share price is 221% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

47.2% of Veru shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Veru. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for Veru. Veru's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Overall Sentiment
Veru	Neutral
Cardiol Therapeutics	Neutral

Veru has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.26	-$22.73M	-$0.69	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Veru presently has a consensus target price of $24.50, indicating a potential upside of 993.75%. Cardiol Therapeutics has a consensus target price of $10.00, indicating a potential upside of 792.86%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Veru beats Cardiol Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$38.19M	$13.02B	$7.59B	$12.54B
Dividend Yield	N/A	2.57%	2.48%	42.78%
P/E Ratio	-3.25	792.44	271.05	25.53
Price / Sales	N/A	933.93	665.27	116.34
Price / Cash	N/A	79.82	76.01	51.38
Price / Book	1.79	9.04	10.62	5.99
Net Income	-$22.73M	$2.86B	$3.51B	$381.97M
7 Day Performance	-2.61%	1.07%	1.17%	-0.45%
1 Month Performance	-11.81%	-7.50%	-7.13%	-7.80%
1 Year Performance	-41.05%	-5.44%	1.60%	-7.22%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.7823 of 5 stars	$2.24 -2.2%	$24.50 +993.8%	-41.1%	$38.19M	N/A	N/A	230
ANTX Anthem	1.526 of 5 stars	$4.30 -2.3%	$9.00 +109.3%	+199.6%	$166.04M	N/A	N/A	N/A	News Coverage
MENS Jyong Biotech	N/A	$2.10 flat	N/A	-97.1%	$159.66M	N/A	N/A	27
SBTX Silverback Therapeutics	N/A	$4.23 -7.2%	N/A	-58.2%	$152.53M	N/A	N/A	83	High Trading Volume
NERV Minerva Neurosciences	1.5162 of 5 stars	$2.89 -9.1%	$10.33 +257.6%	-51.1%	$151.84M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 10/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. ANTX, MENS, SBTX, NERV, and CRDL

How does Veru compare to Anthem?

Summary

How does Veru compare to Jyong Biotech?

Summary

How does Veru compare to Silverback Therapeutics?

Summary

How does Veru compare to Minerva Neurosciences?

Summary

How does Veru compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. ANTX, MENS, SBTX, NERV, and CRDL

How does Veru compare to Anthem?

Do institutionals and insiders hold more shares of ANTX or VERU?

Is ANTX or VERU more profitable?

Which has stronger earnings & valuation, ANTX or VERU?

Which has more volatility & risk, ANTX or VERU?

Does the media refer more to ANTX or VERU?

Do analysts recommend ANTX or VERU?

Summary

How does Veru compare to Jyong Biotech?

Do institutionals and insiders believe in VERU or MENS?

Does the media prefer VERU or MENS?

Which has more risk & volatility, VERU or MENS?

Is VERU or MENS more profitable?

Which has preferable valuation & earnings, VERU or MENS?

Do analysts recommend VERU or MENS?

Summary

How does Veru compare to Silverback Therapeutics?

Which has more volatility and risk, VERU or SBTX?

Do analysts prefer VERU or SBTX?

Which has better earnings & valuation, VERU or SBTX?

Does the media prefer VERU or SBTX?

Is VERU or SBTX more profitable?

Do insiders & institutionals believe in VERU or SBTX?

Summary

How does Veru compare to Minerva Neurosciences?

Is NERV or VERU more profitable?

Which has more risk & volatility, NERV or VERU?

Do insiders & institutionals hold more shares of NERV or VERU?

Which has better valuation and earnings, NERV or VERU?

Does the media favor NERV or VERU?

Do analysts recommend NERV or VERU?

Summary

How does Veru compare to Cardiol Therapeutics?

Is VERU or CRDL more profitable?

Which has more volatility and risk, VERU or CRDL?

Do institutionals and insiders believe in VERU or CRDL?

Does the media refer more to VERU or CRDL?

Which has higher earnings and valuation, VERU or CRDL?

Do analysts prefer VERU or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools